世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
オンコロジー用マウスモデルの市場調査。北米が世界市場の半分近くを占めるMarket Study on Oncology Mice Models: North America Accounts for Nearly Half Global Market Share オンコロジー・マウスモデル市場 - レポートの範囲 Persistence Market Research社が発行した腫瘍マウスモデル市場に関する最新刊は、機会や現在の市場状況を評価し、市場に影響を与える対応するセクションに... もっと見る
サマリーオンコロジー・マウスモデル市場 - レポートの範囲Persistence Market Research社が発行した腫瘍マウスモデル市場に関する最新刊は、機会や現在の市場状況を評価し、市場に影響を与える対応するセクションに関する詳細な分析と最新情報を提供しています。この調査は、市場の促進要因、抑制要因、傾向、機会など、現在の市場力学に関する詳細な洞察を提供します。市場調査の主な目的は、市場が2022年から2032年の予測期間中にどのように推移するかについての独占的な情報を提示することです。 市場の成功成長のための重要な指標は、この包括的なレポートで提示されており、市場の前年比（YoY）成長分析、複合年間成長率（CAGR）など、Persistence Market Research社の調査において網羅的に記述されています。この調査研究は、読者が調査期間中の腫瘍マウスモデルの需要や定量的な開発機会を知るための支援となる。 この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、腫瘍マウスモデル市場で繁栄するために適切なビジネス戦略を開発する際に役立ちます。このPersistence Market Researchの調査で示された洞察と情報は、腫瘍マウスモデル市場の株主、業界専門家、投資家、研究者、記者、ビジネス愛好家が活用することが可能である。 市場統計、および腫瘍マウスモデル市場のビジネスシナリオに影響を与えるマクロ経済変数だけでなくミクロ経済変数にリンクされた情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートで遭遇することができます。さらに、このレポートで提出されたデータによって、業界のマイナーな企業や新規参入者は、市場で牽引力を得るために適切な企業選択をする際に支援されることができます。 主要な市場セグメント Persistence Market Researchの腫瘍マウスモデル市場に関する調査では、製品、エンドユーザー、地域という3つの重要なセグメントに分けられた情報を提供しています。本レポートは、これらのカテゴリに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供しています。 製品 ヒト化免疫系マウスモデル 遺伝子組換え腫瘍マウスモデル 免疫不全マウス NOGマウスモデル 自然発症腫瘍マウス その他 エンドユーザー 受託研究機関 製薬会社・バイオファーマ 学術・研究機関 地域別 北アメリカ ラテンアメリカ ヨーロッパ アジア太平洋地域 中東・アフリカ（MEA） 報告書に記載されている主な質問 今後数年間、腫瘍モデルマウスで最も収益性の高い市場を維持し続けるのはどの地域か？ トレンドの変化は市場にどのような影響を与えるのか？ COVID-19危機は市場の成長にどのような影響を与えたか？ 市場参加者はどのようにして先進地域の低空飛行の機会を捕らえることができるのか？ 市場におけるステークホルダーの戦略はどのようなものですか？ 投資家が認識する必要があり、市場への投資中に取り組む可能性がある抑制要因は何か？ 市場に影響を与えるであろう開発動向は何か？ 腫瘍マウスモデル市場の企業は、先進国および新興国での成長機会をどのように利用することができるのか？ 調査方法 Persistence Market Research社の調査では、腫瘍マウスモデル市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論を得るために、独自の調査手法を活用しています。この調査手法は、一次調査と二次調査の組み合わせであり、アナリストが結論の正確性と信頼性を確保するのに役立ちます。 市場調査作成時にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行いました。 一次および二次リソースから取得した包括的な情報は、市場の企業からの検証として機能し、腫瘍マウスモデル市場の成長見通しに関するPersistence Market Research社の予測をより正確で信頼性の高いものにしています 目次1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Oncology Drugs – Pipeline Analysis 4.1.1. By Intervention 4.1.2. By Phase 4.1.3. By Funding Authority 4.2. Immuno-Oncology Drugs – Pipeline Analysis 4.2.1. By Phase 4.2.2. By Funding Authority 4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials 4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials 4.5. List of Preclinical CROs 4.6. Parent Market Analysis 4.7. Relative Number of Combination Oncology Therapy Trials 4.8. Landscape of Immuno-Oncology Drug Development 4.9. List of Preclinical immuno-oncology models 4.9.1. Cell lines 4.9.2. Mice Models 4.9.3. Organoids/ spheroids 4.10. Key Regulatory Scenario 4.11. Porter’s Analysis 4.12. PESTLE Analysis 4.13. Supply Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. Covid-19 Pandemic 5.2.2. Prevalence of cancer 5.2.3. Rise in R&D investments 5.2.4. Stringent Regulations 5.2.5. Rise in number of pre-clinical and clinical studies 5.2.6. Increasing investment in Cancer research 5.2.7. GDP Growth 5.2.8. Advancements in Models 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as compared to 2008 Economic analysis 6.4. COVID19 and Impact Analysis 6.5. Recovery Scenario – Short term, Midterm, and Long Term Impact 7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017– 2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032 8.3.1. Humanized Immune System Mice Models 8.3.2. Syngeneic Tumor Mice Models 8.3.3. Immunodeficient Mice Models 8.3.4. NOG Mice Models 8.3.5. Spontaneous Tumor Mice Models 8.3.6. Others 8.4. Market Attractiveness Analysis By Product 9. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032 9.3.1. Contract Research Organizations 9.3.2. Pharma and Biopharma Companies 9.3.3. Academic and Research Institutes 9.4. Market Attractiveness Analysis By Indication 10. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032 10.3.1. The North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Asia Pacific 10.3.5. Middle East and Africa (MEA) 10.4 Market Attractiveness Analysis 11. North America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 11.3.1. By Country 11.3.2. By Product 11.3.3. By End User 11.4. Market Attractiveness Analysis 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 12. Latin America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 12.3.1. By Country 12.3.2. By Product 12.3.3. By End User 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Europe Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 13.3.1. By Country 13.3.2. By Product 13.3.3. By End User 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Asia Pacific Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 14.3.1. By Country 14.3.2. By Product 14.3.3. By End User 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 15.3.1. By Country 15.3.2. By Product 15.3.3. By End User 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032 16.1. Introduction 16.1.1. Market Value Proportion Analysis 16.1.2. Global VS. Country Growth Comparison 16.2. U.S. Medical Cart Market Analysis 16.2.1. By Product 16.2.2. By End User 16.3. Canada Medical Cart Market Analysis 16.3.1. By Product 16.3.2. By End User 16.4. Brazil Medical Cart Market Analysis 16.4.1. By Product 16.4.2. By End User 16.5. Argentina Medical Cart Market Analysis 16.5.1. By Product 16.5.2. By End User 16.6. Mexico Medical Cart Market Analysis 16.6.1. By Product 16.6.2. By End User 16.7. Germany Medical Cart Market Analysis 16.7.1. By Product 16.7.2. By End User 16.8. Italy Medical Cart Market Analysis 16.8.1. By Product 16.8.2. By End User 16.9. France Medical Cart Market Analysis 16.9.1. By Product 16.9.2. By End User 16.10. U.K. Medical Cart Market Analysis 16.10.1. By Product 16.10.2. By End User 16.11. Spain Medical Cart Market Analysis 16.11.1. By Product 16.11.2. By End User 16.12. BENELUX Medical Cart Market Analysis 16.12.1. By Product 16.12.2. By End User 16.13. Russia Medical Cart Market Analysis 16.13.1. By Product 16.13.2. By End User 16.14. China Medical Cart Market Analysis 16.14.1. By Product 16.14.2. By End User 16.15. Japan Medical Cart Market Analysis 16.15.1. By Product 16.15.2. By End User 16.16. India Medical Cart Market Analysis 16.16.1. By Product 16.16.2. By End User 16.17. Australia and New Zealand Medical Cart Market Analysis 16.17.1. By Product 16.17.2. By End User 16.18. GCC Countries Medical Cart Market Analysis 16.18.1. By Product 16.18.2. By End User 16.19. South Africa Medical Cart Market Analysis 16.19.1. By Product 16.19.2. By End User 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Share Analysis of Top Players 18. Competition Analysis 18.1. Competition Benchmarking 18.2. Competition Dashboard 18.3. Competition Deep Dive 18.3.1. The Jackson Laboratory 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Key Financials 18.3.1.4. SWOT Analysis 18.3.1.5. Sales Footprint 18.3.1.6. Strategy Overview 18.3.1.6.1. Marketing Strategy 18.3.1.6.2. Product Strategy 18.3.1.6.3. Channel Strategy 18.3.2. Taconic Biosciences 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Key Financials 18.3.2.4. SWOT Analysis 18.3.2.5. Sales Footprint 18.3.2.6. Strategy Overview 18.3.2.6.1. Marketing Strategy 18.3.2.6.2. Product Strategy 18.3.2.6.3. Channel Strategy 18.3.3. Charles River Laboratories 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Key Financials 18.3.3.4. SWOT Analysis 18.3.3.5. Sales Footprint 18.3.3.6. Strategy Overview 18.3.3.6.1. Marketing Strategy 18.3.3.6.2. Product Strategy 18.3.3.6.3. Channel Strategy 18.3.4. Shanghai Model Organisms Center Inc. 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Key Financials 18.3.4.4. SWOT Analysis 18.3.4.5. Sales Footprint 18.3.4.6. Strategy Overview 18.3.4.6.1. Marketing Strategy 18.3.4.6.2. Product Strategy 18.3.4.6.3. Channel Strategy 18.3.5. Envigo 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Key Financials 18.3.5.4. SWOT Analysis 18.3.5.5. Sales Footprint 18.3.5.6. Strategy Overview 18.3.5.6.1. Marketing Strategy 18.3.5.6.2. Product Strategy 18.3.5.6.3. Channel Strategy 18.3.6. Biocytogen 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Key Financials 18.3.6.4. SWOT Analysis 18.3.6.5. Sales Footprint 18.3.6.6. Strategy Overview 18.3.6.6.1. Marketing Strategy 18.3.6.6.2. Product Strategy 18.3.6.6.3. Channel Strategy 18.3.7. Genoway 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Key Financials 18.3.7.4. SWOT Analysis 18.3.7.5. Sales Footprint 18.3.7.6. Strategy Overview 18.3.7.6.1. Marketing Strategy 18.3.7.6.2. Product Strategy 18.3.7.6.3. Channel Strategy 18.3.8. Crown Bioscience Inc. (JSR Corporation). 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Key Financials 18.3.8.4. SWOT Analysis 18.3.8.5. Sales Footprint 18.3.8.6. Strategy Overview 18.3.8.6.1. Marketing Strategy 18.3.8.6.2. Product Strategy 18.3.8.6.3. Channel Strategy 18.3.9. Cyagen 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Key Financials 18.3.9.4. SWOT Analysis 18.3.9.5. Sales Footprint 18.3.9.6. Strategy Overview 18.3.9.6.1. Marketing Strategy 18.3.9.6.2. Product Strategy 18.3.9.6.3. Channel Strategy 18.3.10. Applied stem cells 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Key Financials 18.3.10.4. SWOT Analysis 18.3.10.5. Sales Footprint 18.3.10.6. Strategy Overview 18.3.10.6.1. Marketing Strategy 18.3.10.6.2. Product Strategy 18.3.10.6.3. Channel Strategy 18.3.11. Ingenious Targeting Laboratory 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Key Financials 18.3.11.4. SWOT Analysis 18.3.11.5. Sales Footprint 18.3.11.6. Strategy Overview 18.3.11.6.1. Marketing Strategy 18.3.11.6.2. Product Strategy 18.3.11.6.3. Channel Strategy 18.3.12. PolyGene - Transgenic mice model company 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Key Financials 18.3.12.4. SWOT Analysis 18.3.12.5. Sales Footprint 18.3.12.6. Strategy Overview 18.3.12.6.1. Marketing Strategy 18.3.12.6.2. Product Strategy 18.3.12.6.3. Channel Strategy 18.3.13. Creative Biolabs 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Key Financials 18.3.13.4. SWOT Analysis 18.3.13.5. Sales Footprint 18.3.13.6. Strategy Overview 18.3.13.6.1. Marketing Strategy 18.3.13.6.2. Product Strategy 18.3.13.6.3. Channel Strategy 18.3.14. TransCure Bioservices 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Key Financials 18.3.14.4. SWOT Analysis 18.3.14.5. Sales Footprint 18.3.14.6. Strategy Overview 18.3.14.6.1. Marketing Strategy 18.3.14.6.2. Product Strategy 18.3.14.6.3. Channel Strategy 18.3.15. Champions Oncology Inc 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Key Financials 18.3.15.4. SWOT Analysis 18.3.15.5. Sales Footprint 18.3.15.6. Strategy Overview 18.3.15.6.1. Marketing Strategy 18.3.15.6.2. Product Strategy 18.3.15.6.3. Channel Strategy 18.3.16. Certis Oncology 18.3.16.1. Overview 18.3.16.2. Product Portfolio 18.3.16.3. Key Financials 18.3.16.4. SWOT Analysis 18.3.16.5. Sales Footprint 18.3.16.6. Strategy Overview 18.3.16.6.1. Marketing Strategy 18.3.16.6.2. Product Strategy 18.3.16.6.3. Channel Strategy 18.3.17. Signature 18.3.17.1. Overview 18.3.17.2. Product Portfolio 18.3.17.3. Key Financials 18.3.17.4. SWOT Analysis 18.3.17.5. Sales Footprint 18.3.17.6. Strategy Overview 18.3.17.6.1. Marketing Strategy 18.3.17.6.2. Product Strategy 18.3.17.6.3. Channel Strategy 18.3.18. Pharmaron 18.3.18.1. Overview 18.3.18.2. Product Portfolio 18.3.18.3. Key Financials 18.3.18.4. SWOT Analysis 18.3.18.5. Sales Footprint 18.3.18.6. Strategy Overview 18.3.18.6.1. Marketing Strategy 18.3.18.6.2. Product Strategy 18.3.18.6.3. Channel Strategy 18.3.19. Laboratory Corporation of America Holdings 18.3.19.1. Overview 18.3.19.2. Product Portfolio 18.3.19.3. Key Financials 18.3.19.4. SWOT Analysis 18.3.19.5. Sales Footprint 18.3.19.6. Strategy Overview 18.3.19.6.1. Marketing Strategy 18.3.19.6.2. Product Strategy 18.3.19.6.3. Channel Strategy 18.3.20. Gempharmatech 18.3.20.1. Overview 18.3.20.2. Product Portfolio 18.3.20.3. Key Financials 18.3.20.4. SWOT Analysis 18.3.20.5. Sales Footprint 18.3.20.6. Strategy Overview 18.3.20.6.1. Marketing Strategy 18.3.20.6.2. Product Strategy 18.3.20.6.3. Channel Strategy 18.3.21. Janvier Labs 18.3.21.1. Overview 18.3.21.2. Product Portfolio 18.3.21.3. Key Financials 18.3.21.4. SWOT Analysis 18.3.21.5. Sales Footprint 18.3.21.6. Strategy Overview 18.3.21.6.1. Marketing Strategy 18.3.21.6.2. Product Strategy 18.3.21.6.3. Channel Strategy 18.3.22. Harbour BioMed 18.3.22.1. Overview 18.3.22.2. Product Portfolio 18.3.22.3. Key Financials 18.3.22.4. SWOT Analysis 18.3.22.5. Sales Footprint 18.3.22.6. Strategy Overview 18.3.22.6.1. Marketing Strategy 18.3.22.6.2. Product Strategy 18.3.22.6.3. Channel Strategy 19. Assumptions and Acronyms Used 20. Research Methodology Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by End User Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Region Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032 Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032 Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032 Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032 Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032 Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032 Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032 Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
SummaryOncology Mice Models Market - Scope of Report Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Oncology Drugs – Pipeline Analysis 4.1.1. By Intervention 4.1.2. By Phase 4.1.3. By Funding Authority 4.2. Immuno-Oncology Drugs – Pipeline Analysis 4.2.1. By Phase 4.2.2. By Funding Authority 4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials 4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials 4.5. List of Preclinical CROs 4.6. Parent Market Analysis 4.7. Relative Number of Combination Oncology Therapy Trials 4.8. Landscape of Immuno-Oncology Drug Development 4.9. List of Preclinical immuno-oncology models 4.9.1. Cell lines 4.9.2. Mice Models 4.9.3. Organoids/ spheroids 4.10. Key Regulatory Scenario 4.11. Porter’s Analysis 4.12. PESTLE Analysis 4.13. Supply Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. Covid-19 Pandemic 5.2.2. Prevalence of cancer 5.2.3. Rise in R&D investments 5.2.4. Stringent Regulations 5.2.5. Rise in number of pre-clinical and clinical studies 5.2.6. Increasing investment in Cancer research 5.2.7. GDP Growth 5.2.8. Advancements in Models 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as compared to 2008 Economic analysis 6.4. COVID19 and Impact Analysis 6.5. Recovery Scenario – Short term, Midterm, and Long Term Impact 7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017– 2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032 8.3.1. Humanized Immune System Mice Models 8.3.2. Syngeneic Tumor Mice Models 8.3.3. Immunodeficient Mice Models 8.3.4. NOG Mice Models 8.3.5. Spontaneous Tumor Mice Models 8.3.6. Others 8.4. Market Attractiveness Analysis By Product 9. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032 9.3.1. Contract Research Organizations 9.3.2. Pharma and Biopharma Companies 9.3.3. Academic and Research Institutes 9.4. Market Attractiveness Analysis By Indication 10. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032 10.3.1. The North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Asia Pacific 10.3.5. Middle East and Africa (MEA) 10.4 Market Attractiveness Analysis 11. North America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 11.3.1. By Country 11.3.2. By Product 11.3.3. By End User 11.4. Market Attractiveness Analysis 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 12. Latin America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 12.3.1. By Country 12.3.2. By Product 12.3.3. By End User 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Europe Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 13.3.1. By Country 13.3.2. By Product 13.3.3. By End User 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Asia Pacific Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 14.3.1. By Country 14.3.2. By Product 14.3.3. By End User 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032 15.3.1. By Country 15.3.2. By Product 15.3.3. By End User 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032 16.1. Introduction 16.1.1. Market Value Proportion Analysis 16.1.2. Global VS. Country Growth Comparison 16.2. U.S. Medical Cart Market Analysis 16.2.1. By Product 16.2.2. By End User 16.3. Canada Medical Cart Market Analysis 16.3.1. By Product 16.3.2. By End User 16.4. Brazil Medical Cart Market Analysis 16.4.1. By Product 16.4.2. By End User 16.5. Argentina Medical Cart Market Analysis 16.5.1. By Product 16.5.2. By End User 16.6. Mexico Medical Cart Market Analysis 16.6.1. By Product 16.6.2. By End User 16.7. Germany Medical Cart Market Analysis 16.7.1. By Product 16.7.2. By End User 16.8. Italy Medical Cart Market Analysis 16.8.1. By Product 16.8.2. By End User 16.9. France Medical Cart Market Analysis 16.9.1. By Product 16.9.2. By End User 16.10. U.K. Medical Cart Market Analysis 16.10.1. By Product 16.10.2. By End User 16.11. Spain Medical Cart Market Analysis 16.11.1. By Product 16.11.2. By End User 16.12. BENELUX Medical Cart Market Analysis 16.12.1. By Product 16.12.2. By End User 16.13. Russia Medical Cart Market Analysis 16.13.1. By Product 16.13.2. By End User 16.14. China Medical Cart Market Analysis 16.14.1. By Product 16.14.2. By End User 16.15. Japan Medical Cart Market Analysis 16.15.1. By Product 16.15.2. By End User 16.16. India Medical Cart Market Analysis 16.16.1. By Product 16.16.2. By End User 16.17. Australia and New Zealand Medical Cart Market Analysis 16.17.1. By Product 16.17.2. By End User 16.18. GCC Countries Medical Cart Market Analysis 16.18.1. By Product 16.18.2. By End User 16.19. South Africa Medical Cart Market Analysis 16.19.1. By Product 16.19.2. By End User 17. Market Structure Analysis 17.1. Market Analysis by Tier of Companies 17.2. Market Share Analysis of Top Players 18. Competition Analysis 18.1. Competition Benchmarking 18.2. Competition Dashboard 18.3. Competition Deep Dive 18.3.1. The Jackson Laboratory 18.3.1.1. Overview 18.3.1.2. Product Portfolio 18.3.1.3. Key Financials 18.3.1.4. SWOT Analysis 18.3.1.5. Sales Footprint 18.3.1.6. Strategy Overview 18.3.1.6.1. Marketing Strategy 18.3.1.6.2. Product Strategy 18.3.1.6.3. Channel Strategy 18.3.2. Taconic Biosciences 18.3.2.1. Overview 18.3.2.2. Product Portfolio 18.3.2.3. Key Financials 18.3.2.4. SWOT Analysis 18.3.2.5. Sales Footprint 18.3.2.6. Strategy Overview 18.3.2.6.1. Marketing Strategy 18.3.2.6.2. Product Strategy 18.3.2.6.3. Channel Strategy 18.3.3. Charles River Laboratories 18.3.3.1. Overview 18.3.3.2. Product Portfolio 18.3.3.3. Key Financials 18.3.3.4. SWOT Analysis 18.3.3.5. Sales Footprint 18.3.3.6. Strategy Overview 18.3.3.6.1. Marketing Strategy 18.3.3.6.2. Product Strategy 18.3.3.6.3. Channel Strategy 18.3.4. Shanghai Model Organisms Center Inc. 18.3.4.1. Overview 18.3.4.2. Product Portfolio 18.3.4.3. Key Financials 18.3.4.4. SWOT Analysis 18.3.4.5. Sales Footprint 18.3.4.6. Strategy Overview 18.3.4.6.1. Marketing Strategy 18.3.4.6.2. Product Strategy 18.3.4.6.3. Channel Strategy 18.3.5. Envigo 18.3.5.1. Overview 18.3.5.2. Product Portfolio 18.3.5.3. Key Financials 18.3.5.4. SWOT Analysis 18.3.5.5. Sales Footprint 18.3.5.6. Strategy Overview 18.3.5.6.1. Marketing Strategy 18.3.5.6.2. Product Strategy 18.3.5.6.3. Channel Strategy 18.3.6. Biocytogen 18.3.6.1. Overview 18.3.6.2. Product Portfolio 18.3.6.3. Key Financials 18.3.6.4. SWOT Analysis 18.3.6.5. Sales Footprint 18.3.6.6. Strategy Overview 18.3.6.6.1. Marketing Strategy 18.3.6.6.2. Product Strategy 18.3.6.6.3. Channel Strategy 18.3.7. Genoway 18.3.7.1. Overview 18.3.7.2. Product Portfolio 18.3.7.3. Key Financials 18.3.7.4. SWOT Analysis 18.3.7.5. Sales Footprint 18.3.7.6. Strategy Overview 18.3.7.6.1. Marketing Strategy 18.3.7.6.2. Product Strategy 18.3.7.6.3. Channel Strategy 18.3.8. Crown Bioscience Inc. (JSR Corporation). 18.3.8.1. Overview 18.3.8.2. Product Portfolio 18.3.8.3. Key Financials 18.3.8.4. SWOT Analysis 18.3.8.5. Sales Footprint 18.3.8.6. Strategy Overview 18.3.8.6.1. Marketing Strategy 18.3.8.6.2. Product Strategy 18.3.8.6.3. Channel Strategy 18.3.9. Cyagen 18.3.9.1. Overview 18.3.9.2. Product Portfolio 18.3.9.3. Key Financials 18.3.9.4. SWOT Analysis 18.3.9.5. Sales Footprint 18.3.9.6. Strategy Overview 18.3.9.6.1. Marketing Strategy 18.3.9.6.2. Product Strategy 18.3.9.6.3. Channel Strategy 18.3.10. Applied stem cells 18.3.10.1. Overview 18.3.10.2. Product Portfolio 18.3.10.3. Key Financials 18.3.10.4. SWOT Analysis 18.3.10.5. Sales Footprint 18.3.10.6. Strategy Overview 18.3.10.6.1. Marketing Strategy 18.3.10.6.2. Product Strategy 18.3.10.6.3. Channel Strategy 18.3.11. Ingenious Targeting Laboratory 18.3.11.1. Overview 18.3.11.2. Product Portfolio 18.3.11.3. Key Financials 18.3.11.4. SWOT Analysis 18.3.11.5. Sales Footprint 18.3.11.6. Strategy Overview 18.3.11.6.1. Marketing Strategy 18.3.11.6.2. Product Strategy 18.3.11.6.3. Channel Strategy 18.3.12. PolyGene - Transgenic mice model company 18.3.12.1. Overview 18.3.12.2. Product Portfolio 18.3.12.3. Key Financials 18.3.12.4. SWOT Analysis 18.3.12.5. Sales Footprint 18.3.12.6. Strategy Overview 18.3.12.6.1. Marketing Strategy 18.3.12.6.2. Product Strategy 18.3.12.6.3. Channel Strategy 18.3.13. Creative Biolabs 18.3.13.1. Overview 18.3.13.2. Product Portfolio 18.3.13.3. Key Financials 18.3.13.4. SWOT Analysis 18.3.13.5. Sales Footprint 18.3.13.6. Strategy Overview 18.3.13.6.1. Marketing Strategy 18.3.13.6.2. Product Strategy 18.3.13.6.3. Channel Strategy 18.3.14. TransCure Bioservices 18.3.14.1. Overview 18.3.14.2. Product Portfolio 18.3.14.3. Key Financials 18.3.14.4. SWOT Analysis 18.3.14.5. Sales Footprint 18.3.14.6. Strategy Overview 18.3.14.6.1. Marketing Strategy 18.3.14.6.2. Product Strategy 18.3.14.6.3. Channel Strategy 18.3.15. Champions Oncology Inc 18.3.15.1. Overview 18.3.15.2. Product Portfolio 18.3.15.3. Key Financials 18.3.15.4. SWOT Analysis 18.3.15.5. Sales Footprint 18.3.15.6. Strategy Overview 18.3.15.6.1. Marketing Strategy 18.3.15.6.2. Product Strategy 18.3.15.6.3. Channel Strategy 18.3.16. Certis Oncology 18.3.16.1. Overview 18.3.16.2. Product Portfolio 18.3.16.3. Key Financials 18.3.16.4. SWOT Analysis 18.3.16.5. Sales Footprint 18.3.16.6. Strategy Overview 18.3.16.6.1. Marketing Strategy 18.3.16.6.2. Product Strategy 18.3.16.6.3. Channel Strategy 18.3.17. Signature 18.3.17.1. Overview 18.3.17.2. Product Portfolio 18.3.17.3. Key Financials 18.3.17.4. SWOT Analysis 18.3.17.5. Sales Footprint 18.3.17.6. Strategy Overview 18.3.17.6.1. Marketing Strategy 18.3.17.6.2. Product Strategy 18.3.17.6.3. Channel Strategy 18.3.18. Pharmaron 18.3.18.1. Overview 18.3.18.2. Product Portfolio 18.3.18.3. Key Financials 18.3.18.4. SWOT Analysis 18.3.18.5. Sales Footprint 18.3.18.6. Strategy Overview 18.3.18.6.1. Marketing Strategy 18.3.18.6.2. Product Strategy 18.3.18.6.3. Channel Strategy 18.3.19. Laboratory Corporation of America Holdings 18.3.19.1. Overview 18.3.19.2. Product Portfolio 18.3.19.3. Key Financials 18.3.19.4. SWOT Analysis 18.3.19.5. Sales Footprint 18.3.19.6. Strategy Overview 18.3.19.6.1. Marketing Strategy 18.3.19.6.2. Product Strategy 18.3.19.6.3. Channel Strategy 18.3.20. Gempharmatech 18.3.20.1. Overview 18.3.20.2. Product Portfolio 18.3.20.3. Key Financials 18.3.20.4. SWOT Analysis 18.3.20.5. Sales Footprint 18.3.20.6. Strategy Overview 18.3.20.6.1. Marketing Strategy 18.3.20.6.2. Product Strategy 18.3.20.6.3. Channel Strategy 18.3.21. Janvier Labs 18.3.21.1. Overview 18.3.21.2. Product Portfolio 18.3.21.3. Key Financials 18.3.21.4. SWOT Analysis 18.3.21.5. Sales Footprint 18.3.21.6. Strategy Overview 18.3.21.6.1. Marketing Strategy 18.3.21.6.2. Product Strategy 18.3.21.6.3. Channel Strategy 18.3.22. Harbour BioMed 18.3.22.1. Overview 18.3.22.2. Product Portfolio 18.3.22.3. Key Financials 18.3.22.4. SWOT Analysis 18.3.22.5. Sales Footprint 18.3.22.6. Strategy Overview 18.3.22.6.1. Marketing Strategy 18.3.22.6.2. Product Strategy 18.3.22.6.3. Channel Strategy 19. Assumptions and Acronyms Used 20. Research Methodology Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by End User Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Region Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032 Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032 Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032 Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032 Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032 Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032 Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032 Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F) Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022 Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022 Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021 Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032 Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032 Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032 Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（薬学的薬物）の最新刊レポートPersistence Market Research社のその他分野での最新刊レポート本レポートと同じKEY WORD（oncology）の最新刊レポート
よくあるご質問Persistence Market Research社はどのような調査会社ですか?パーシスタンスマーケットリサーチ（Persistence Market Research/PMR）は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |
